S&P Futures
3,914.00-8.50(-0.22%)Dow Futures
31,935.00+19.00(+0.06%)Nasdaq Futures
13,198.25-103.75(-0.78%)
Oramed Pharmaceuticals Inc. (ORMP)
9.90 +0.53 (5.66%)
Pre-Market: 6:46AM EST
Chart Events
Performance Outlook
| Previous Close | 8.91 |
| Open | 9.00 |
| Bid | 9.58 x 900 |
| Ask | 0.00 x 2200 |
| Day's Range | 8.98 - 9.59 |
| 52 Week Range | 2.40 - 11.71 |
| Volume | 272,691 |
| Avg. Volume | 954,936 |
| Market Cap | 275.201M |
| Beta (5Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.66 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.83 |
- PR Newswire
Oramed Issues Letter to Shareholders
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery technology, is pleased to provide the following Letter to Shareholders from Chief Executive Officer Nadav Kidron.
- PR Newswire
Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery, announced today that randomization of patients in its first Phase 3 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D) is under way. The study is being conducted in accordance with U.S. Food and Drug Administration (FDA) approved protocols.
- Simply Wall St.
We're Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
